MARAVAI LIFESCIENCES HOLDINGS, INC.
MRVI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MRVI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MRVI
Maravai LifeSciences Holdings, Inc. (MRVI) is a life sciences products company that provides critical reagents and services for nucleic acid production, biologics safety testing, and protein labeling to biopharmaceutical and research customers.
Key risk: CleanCap revenue concentration
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$2.84B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Maravai LifeSciences Holdings, Inc. (MRVI) is a life sciences products company that provides critical reagents and services for nucleic acid production, biologics safety testing, and protein labeling to biopharmaceutical and research customers.
- Operates through two reportable segments: TriLink and Cygnus [sec_mda · as of 2026-08-07].
- Revenue from high-volume sales of CleanCap for commercial phase vaccine programs represented approximately 25.4% of total revenues for the year ended December 31, 2024 [sec_mda · as of 2025-03-18].
- As of June 30, 2026, employed 415 full-time employees, approximately 26% with advanced degrees [sec_mda · as of 2026-08-07].
- As of 2026-06-30, cash & equivalents $70.6M, total revenue $51.4M, net income -$12.4M, shareholders' equity $265.9M, total debt $148.2M [sec].
- In 2024, the company recorded a goodwill impairment due to lower projected near-term revenues in its Nucleic Acid Production business [sec_mda · as of 2024-11-12].
What works
- Maravai serves a diversified customer base including leading biopharmaceutical, vaccine, diagnostics, and gene and cell therapy companies, as well as government and academic institutions [sec_mda · as of 2025-05-12].
- The company has a proprietary product, CleanCap, which has been a significant revenue driver, contributing approximately 25.4% of total revenue in 2024 [sec_mda · as of 2025-03-18].
- Management has experience working with a range of biopharmaceutical and research customers and continues to invest in R&D and new products to support customer needs [sec_mda · as of 2025-03-18].
What to weigh
- Revenue from high-volume CleanCap orders for commercial vaccine programs is difficult to forecast because historical customers have been unable or unwilling to provide visibility into future needs [sec_mda · as of 2025-03-18].
- The company recorded a goodwill impairment in 2024 due to lower projected near-term revenues in its Nucleic Acid Production business [sec_mda · as of 2024-11-12].
- In 2025, the company implemented a reduction in force, reducing headcount from over 580 to approximately 440 employees [sec_mda · as of 2025-11-07].
- Revenue for the six months ended June 30, 2025, included $33.4 million in high-volume CleanCap sales that did not recur in the same period of 2025, indicating volatility [sec_mda · as of 2025-08-11].
From the filings
Quoted directly from source documents.
CleanCap revenue concentration and forecasting difficulty
“revenue from high-volume sales of CleanCap for commercial phase vaccine programs represented approximately 25.4% and 21.0% of our total revenues for the years ended December 31, 2024 and 2023, respectively. The amount, timing and durability of future high-volume CleanCap orders have become increasingly difficult to forecast because historical customers for such orders have been unable or unwilling to provide visibility into their anticipated future needs and plans to purchase CleanCap.”
SEC MD&A · March 18, 2025
Goodwill impairment due to lower revenue forecast
“We revised our long-term forecast to reflect lower projected near term revenues due to lower demand in research and discovery products within our Nucleic Acid Production business.”
SEC MD&A · November 12, 2024
Reduction in force in 2025
“As of November 4, 2025, following the substantial completion of a reduction in force (as described under "2025 Corporate Realignment Plan" below), we had approximately 440 employees, approximately 26% of whom have advanced degrees.”
SEC MD&A · November 7, 2025
Revenue decline due to non-recurring CleanCap sales
“Revenue for the six months ended June 30, 2024, included $33.4 million in sales for high-volume CleanCap for commercialized vaccine programs that did not recur in the six months ended June 30, 2025.”
SEC MD&A · August 11, 2025
Risks & what to watch (4)›
Key risks
- CleanCap revenue concentration — High-volume CleanCap orders are difficult to forecast and may not recur, significantly impacting revenue and cash flow [sec_mda · as of 2025-03-18].
- Goodwill impairment risk — The company recorded a goodwill impairment in 2024 due to lower demand in Nucleic Acid Production, indicating potential further impairment [sec_mda · as of 2024-11-12].
- Workforce reduction impact — A reduction in force in 2025 reduced headcount by over 140 employees, which may affect operational capacity [sec_mda · as of 2025-11-07].
- Customer visibility and demand — Customers are unable or unwilling to provide visibility into future CleanCap orders, creating uncertainty in revenue forecasting [sec_mda · as of 2025-03-18].
What to watch
- Future high-volume CleanCap orders and their recurrence, as they are a significant revenue driver [sec_mda · as of 2025-03-18].
- Demand trends in the Nucleic Acid Production segment, which led to a goodwill impairment in 2024 [sec_mda · as of 2024-11-12].
- Impact of the 2025 corporate realignment and reduction in force on operational efficiency and costs [sec_mda · as of 2025-11-07].
- International sales performance, particularly in Europe and Asia Pacific, which are served through distributors and direct sales [sec_mda · as of 2025-08-11].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run MARAVAI LIFESCIENCES HOLDINGS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MARAVAI LIFESCIENCES HOLDINGS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 1.21 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 2 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
157
Total value held
$344.8M
| Holder | Shares | Value |
|---|---|---|
| gtcr llc | 20,150,005 | $57.0M |
| vanguard capital management llc | 10,899,404 | $30.8M |
| braidwell lp | 10,240,164 | $29.0M |
| blackrock, inc. | 9,345,268 | $26.4M |
| 12 west capital management lp | 7,260,195 | $20.5M |
| mackenzie financial corp | 6,306,425 | $17.8M |
| first eagle investment management, llc | 5,048,672 | $14.3M |
| renaissance technologies llc | 4,264,689 | $12.1M |
| morgan stanley | 3,319,325 | $9.4M |
| point72 asset management, l.p. | 3,205,496 | $9.1M |
Showing top 10 of 157 institutional holders of MARAVAI LIFESCIENCES HOLDINGS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 7.7%
- Days to cover
- 5.3
- Shares short
- 9,510,334
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MRVI short interestGovernance
Frequently asked questions
What is the AI investment thesis for MARAVAI LIFESCIENCES HOLDINGS, INC.?
Maravai LifeSciences Holdings, Inc. (MRVI) is a life sciences products company that provides critical reagents and services for nucleic acid production, biologics safety testing, and protein labeling to biopharmaceutical and research customers.
Who is the CEO of MARAVAI LIFESCIENCES HOLDINGS, INC.?
Mr. Bernd Brust is the chief executive officer of MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI).
Where is MARAVAI LIFESCIENCES HOLDINGS, INC. headquartered?
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) is headquartered in San Diego, CA, United States.
What therapeutic areas does MARAVAI LIFESCIENCES HOLDINGS, INC. focus on?
MARAVAI LIFESCIENCES HOLDINGS, INC. develops therapies across Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.